2023
Cellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell types
2019
Novel immunological and clinical insights in vascularized composite allotransplantation
Kollar B, Pomahac B, Riella L. Novel immunological and clinical insights in vascularized composite allotransplantation. Current Opinion In Organ Transplantation 2019, 24: 42-48. PMID: 30531538, DOI: 10.1097/mot.0000000000000592.Peer-Reviewed Original ResearchConceptsAcute rejectionT cellsComposite allotransplantationField of VCANovel immunosuppressive approachAntibody-mediated rejectionCurrent histological classificationNovel noninvasive biomarkersQuality of lifeType of rejectionIntensity of treatmentFace transplant recipientsChronic rejectionImmunosuppressive regimensVCA patientsVCA recipientsAllograft injuryCostimulation blockadeImmunosuppressive approachesImmunosuppressive therapyTransplant recipientsImmune monitoringUpper extremityHistological classificationVCA outcomes
2018
Kidney Dysfunction After Vascularized Composite Allotransplantation
Krezdorn N, Tasigiorgos S, Wo L, Lopdrup R, Turk M, Kiwanuka H, Ahmed S, Petruzzo P, Bueno E, Pomahac B, Riella L. Kidney Dysfunction After Vascularized Composite Allotransplantation. Transplantation Direct 2018, 4: e362. PMID: 30046652, PMCID: PMC6056276, DOI: 10.1097/txd.0000000000000795.Peer-Reviewed Original ResearchGlomerular filtration rateKidney dysfunctionCreatinine levelsTrough levelsRisk factorsCalcineurin inhibitor trough levelsNonrenal solid organ transplantsLong-term patient outcomesFirst year posttransplantSuccessful midterm outcomesRenal risk factorsSolid organ transplantsAlternative immunosuppressive agentsComposite tissue transplantationAcute rejectionVCA patientsYear posttransplantMidterm outcomesRenal dysfunctionIR patientsKidney complicationsRenal functionMajor complicationsImmunosuppressive agentsKidney parameters
2017
Role of Facial Vascularized Composite Allotransplantation in Burn Patients
Bharadia D, Sinha I, Pomahac B. Role of Facial Vascularized Composite Allotransplantation in Burn Patients. Clinics In Plastic Surgery 2017, 44: 857-864. PMID: 28888310, DOI: 10.1016/j.cps.2017.05.017.Peer-Reviewed Original ResearchConceptsComposite allotransplantationFacial Vascularized Composite AllotransplantationExtensive burn injuriesRisk of rejectionVascularized Composite AllotransplantationQuality of lifeLifelong regimenVCA patientsImmunosuppression medicationsPowerful reconstructive toolsBurn patientsTreatment optionsSurgical techniqueBurn injuryReconstructive surgeryPatientsReconstructive toolFace transplantationAllotransplantationImproved qualityFacial formImmunosuppressionMedicationsRegimenSurgery